These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 27140858)

  • 21. Effect of dose and plasma concentration on liver uptake and pharmacologic activity of a 2'-methoxyethyl modified chimeric antisense oligonucleotide targeting PTEN.
    Geary RS; Wancewicz E; Matson J; Pearce M; Siwkowski A; Swayze E; Bennett F
    Biochem Pharmacol; 2009 Aug; 78(3):284-91. PubMed ID: 19393225
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Chronic Toxicity Assessment of 2'-O-Methoxyethyl Antisense Oligonucleotides in Mice.
    Zanardi TA; Kim TW; Shen L; Serota D; Papagiannis C; Park SY; Kim Y; Henry SP
    Nucleic Acid Ther; 2018 Aug; 28(4):233-241. PubMed ID: 29708844
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Safety, Pharmacokinetic, and Pharmacodynamic Evaluation of a 2'-(2-Methoxyethyl)-D-ribose Antisense Oligonucleotide-Triantenarry
    Zanardi TA; Korbmacher B; Boone L; Engelhardt JA; Wang Y; Burel S; Prill B; Aghajan M; Guo S; Henry SP
    J Pharmacol Exp Ther; 2021 Apr; 377(1):51-63. PubMed ID: 33431610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Single-dose hemodynamic toxicity and pharmacokinetics of a partial phosphorothioate anti-HIV oligonucleotide (AR177) after intravenous infusion to cynomolgus monkeys.
    Wallace TL; Bazemore SA; Kornbrust DJ; Cossum PA
    J Pharmacol Exp Ther; 1996 Sep; 278(3):1306-12. PubMed ID: 8819516
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Reduction in ocular complement factor B protein in mice and monkeys by systemic administration of factor B antisense oligonucleotide.
    Grossman TR; Carrer M; Shen L; Johnson RB; Hettrick LA; Henry SP; Monia BP; McCaleb ML
    Mol Vis; 2017; 23():561-571. PubMed ID: 28855795
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vivo delivery of antisense oligonucleotides in pH-sensitive liposomes inhibits lipopolysaccharide-induced production of tumor necrosis factor-alpha in rats.
    Ponnappa BC; Dey I; Tu GC; Zhou F; Aini M; Cao QN; Israel Y
    J Pharmacol Exp Ther; 2001 Jun; 297(3):1129-36. PubMed ID: 11356938
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Co-Administration of an Excipient Oligonucleotide Helps Delineate Pathways of Productive and Nonproductive Uptake of Phosphorothioate Antisense Oligonucleotides in the Liver.
    Donner AJ; Wancewicz EV; Murray HM; Greenlee S; Post N; Bell M; Lima WF; Swayze EE; Seth PP
    Nucleic Acid Ther; 2017 Aug; 27(4):209-220. PubMed ID: 28448194
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Suppressing transthyretin production in mice, monkeys and humans using 2nd-Generation antisense oligonucleotides.
    Ackermann EJ; Guo S; Benson MD; Booten S; Freier S; Hughes SG; Kim TW; Jesse Kwoh T; Matson J; Norris D; Yu R; Watt A; Monia BP
    Amyloid; 2016 Sep; 23(3):148-157. PubMed ID: 27355239
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Disposition and Pharmacokinetics of a GalNAc3-Conjugated Antisense Oligonucleotide Targeting Human Lipoprotein (a) in Monkeys.
    Yu RZ; Gunawan R; Post N; Zanardi T; Hall S; Burkey J; Kim TW; Graham MJ; Prakash TP; Seth PP; Swayze EE; Geary RS; Henry SP; Wang Y
    Nucleic Acid Ther; 2016 Dec; 26(6):372-380. PubMed ID: 27500733
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chemical modification of PS-ASO therapeutics reduces cellular protein-binding and improves the therapeutic index.
    Shen W; De Hoyos CL; Migawa MT; Vickers TA; Sun H; Low A; Bell TA; Rahdar M; Mukhopadhyay S; Hart CE; Bell M; Riney S; Murray SF; Greenlee S; Crooke RM; Liang XH; Seth PP; Crooke ST
    Nat Biotechnol; 2019 Jun; 37(6):640-650. PubMed ID: 31036929
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Tissue disposition of 2'-O-(2-methoxy) ethyl modified antisense oligonucleotides in monkeys.
    Yu RZ; Geary RS; Monteith DK; Matson J; Truong L; Fitchett J; Levin AA
    J Pharm Sci; 2004 Jan; 93(1):48-59. PubMed ID: 14648635
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Application of 2'-O-(2-N-Methylcarbamoylethyl) Nucleotides in RNase H-Dependent Antisense Oligonucleotides.
    Masaki Y; Iriyama Y; Nakajima H; Kuroda Y; Kanaki T; Furukawa S; Sekine M; Seio K
    Nucleic Acid Ther; 2018 Oct; 28(5):307-311. PubMed ID: 30020852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antitumor activity of antisense clusterin oligonucleotides is improved in vitro and in vivo by incorporation of 2'-O-(2-methoxy)ethyl chemistry.
    Zellweger T; Miyake H; Cooper S; Chi K; Conklin BS; Monia BP; Gleave ME
    J Pharmacol Exp Ther; 2001 Sep; 298(3):934-40. PubMed ID: 11504787
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Assessment of the Effect of Organ Impairment on the Pharmacokinetics of 2'-MOE and Phosphorothioate Modified Antisense Oligonucleotides.
    Wang Y; Diep JK; Yu RZ; Hurh E; Karwatowska-Prokopczuk E; Schneider E; Henry S; Bhanot S; Geary RS
    J Clin Pharmacol; 2023 Jan; 63(1):21-28. PubMed ID: 35801818
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hsp90 protein interacts with phosphorothioate oligonucleotides containing hydrophobic 2'-modifications and enhances antisense activity.
    Liang XH; Shen W; Sun H; Kinberger GA; Prakash TP; Nichols JG; Crooke ST
    Nucleic Acids Res; 2016 May; 44(8):3892-907. PubMed ID: 26945041
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Cross-species comparison of in vivo PK/PD relationships for second-generation antisense oligonucleotides targeting apolipoprotein B-100.
    Yu RZ; Lemonidis KM; Graham MJ; Matson JE; Crooke RM; Tribble DL; Wedel MK; Levin AA; Geary RS
    Biochem Pharmacol; 2009 Mar; 77(5):910-9. PubMed ID: 19056355
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Species-specific inflammatory responses as a primary component for the development of glomerular lesions in mice and monkeys following chronic administration of a second-generation antisense oligonucleotide.
    Frazier KS; Sobry C; Derr V; Adams MJ; Besten CD; De Kimpe S; Francis I; Gales TL; Haworth R; Maguire SR; Mirabile RC; Mullins D; Palate B; Doorten YP; Ridings JE; Scicchitano MS; Silvano J; Woodfine J
    Toxicol Pathol; 2014 Jul; 42(5):923-35. PubMed ID: 24292388
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antisense inhibition of coagulation factor XI prolongs APTT without increased bleeding risk in cynomolgus monkeys.
    Younis HS; Crosby J; Huh JI; Lee HS; Rime S; Monia B; Henry SP
    Blood; 2012 Mar; 119(10):2401-8. PubMed ID: 22246038
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Assessment of the Effects of 2'-Methoxyethyl Antisense Oligonucleotides on Platelet Count in Cynomolgus Nonhuman Primates.
    Henry SP; Narayanan P; Shen L; Bhanot S; Younis HS; Burel SA
    Nucleic Acid Ther; 2017 Aug; 27(4):197-208. PubMed ID: 28541820
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Absolute bioavailability of 2'-O-(2-methoxyethyl)-modified antisense oligonucleotides following intraduodenal instillation in rats.
    Geary RS; Khatsenko O; Bunker K; Crooke R; Moore M; Burckin T; Truong L; Sasmor H; Levin AA
    J Pharmacol Exp Ther; 2001 Mar; 296(3):898-904. PubMed ID: 11181922
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.